A company insider recently sold 11,123 shares of Amicus Therapeutics Inc. [FOLD]. Should You Sale?

Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Amicus Therapeutics Inc. shares valued at $111,472 were sold by Rosenberg Ellen on Aug 01. At $10.02 per share, Rosenberg Ellen sold 11,123 shares. The insider’s holdings dropped to 280,707 shares worth approximately $3.07 million following the completion of this transaction.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Also, Crowley John F sold 11,346 shares, netting a total of over 113,029 in proceeds. Following the sale of shares at $9.96 each, the insider now holds 889,179 shares.

Before that, Campbell Bradley L had sold 5,470 shares from its account. In a trade valued at $54,883, the President & CEO traded Amicus Therapeutics Inc. shares for $10.03 each. Upon closing the transaction, the insider’s holdings decreased to 5,470 shares, worth approximately $7.54 million.

Analysts at SVB Leerink upgraded the stock from ‘”a Mkt perform”‘ to ‘”an Outperform”‘ outlook in a report released in mid January. As of November 15, 2021, Stifel has increased its “Hold” rating to a “Buy” for FOLD. Earlier on September 30, 2021, JP Morgan upgraded its rating. Their new recommendation was “an Overweight” for FOLD stock which previously was a “a Neutral”.

Analyzing FOLD’s Price Performance

On Thursday, Amicus Therapeutics Inc. [NASDAQ: FOLD] rose 5.50% to $10.94. The stock’s lowest price that day was $10.29, but it reached a high of $10.94 in the same session. During the last five days, there has been a surge of approximately 4.99%. Over the course of the year, Amicus Therapeutics Inc. shares have dropped approximately -5.28%. Shares of the company reached a 52-week high of $12.63 on 01/05/22 and a 52-week low of $5.91 on 05/09/22. A 50-day SMA is recorded $9.77, while a 200-day SMA reached $9.65. Nevertheless, trading volume fell to 7.49 million shares from 1.92 million shares the previous day.

Support And Resistance Levels for Amicus Therapeutics Inc. (FOLD)

According to the 24-hour chart, there is a support level at 10.51, which, if violated, would cause prices to drop to 10.07. In the upper region, resistance lies at 11.16. The next price resistance is at 11.37. RSI (Relative Strength Index) is 58.98 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.06, which suggests the price will decrease in the coming days. Percent R is at 23.44%, indicating bullish price movement. Stochastics %K at holding indicates that the stock is to be held.

Is Amicus Therapeutics Inc. subject to short interest?

Stocks of Amicus Therapeutics Inc. saw a sharp steep in short interest on Jul 14, 2022 dropping by -8.18 million shares to 21.75 million. Data from Yahoo Finance shows that the short interest on Jun 14, 2022 was 29.93 million shares. A decline of -37.61% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 5.78 of the overall float, the days-to-cover ratio (short ratio) decline to 5.78.

Which companies own the most shares of Amicus Therapeutics Inc. (FOLD)?

According to Perceptive Advisors LLC filings, the company currently owns 27,555,845 shares, which is about 9.84% of the total FOLD shares outstanding. The investor’s shares have appreciated by 996,402 from its previous 13-F filing of 26559443.0 shares. With the completion of the sale transaction, Wellington Management Co. LLP’s stake is now worth $285,889,209. The Vanguard Group, Inc. acquire a 0.16% interest valued at $268.35 million while Redmile Group LLC sold a -386,700 stake. A total of 2,000,000 shares of Amicus Therapeutics Inc. were sold by Avoro Capital Advisor LLC during the quarter, and -222,497 were sold by BlackRock Fund Advisors. In its current portfolio, Morgan Stanley & Co. LLC holds 16,727,423 shares valued at $179.65 million.

In terms of Amicus Therapeutics Inc. share price expectations, FactSet research, analysts set an average price target of $14.50 in the next 12 months, up nearly 39.83% from the previous closing price of $10.37. Analysts anticipate Amicus Therapeutics Inc. stock to reach $20.00 by 2022, with the lowest price target being $10.00. In spite of this, 12 analysts ranked Amicus Therapeutics Inc. stock as an Overweight at the end of 2022. On July 19, 2021, BTIG Research assigned a price target of “a Buy” to the stock and resumed coverage with a $15.


Please enter your comment!
Please enter your name here